{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:08:18Z","timestamp":1789409298885,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T00:00:00Z","timestamp":1492473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T00:00:00Z","timestamp":1492473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1038\/tpj.2017.6","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T10:00:33Z","timestamp":1492509633000},"page":"304-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["More than 25 years of genetic studies of clozapine-induced agranulocytosis"],"prefix":"10.1038","volume":"17","author":[{"given":"S A J","family":"de With","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S L","family":"Pulit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W G","family":"Staal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R S","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Ophoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,18]]},"reference":[{"key":"BFtpj20176_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(75)90135-X","volume":"306","author":"RWW Griffith","year":"1975","unstructured":"Griffith RWW, Saameli K . Clozapine and agranulocytosis. Lancet 1975; 306: 657.","journal-title":"Lancet"},{"key":"BFtpj20176_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H . Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789\u2013796.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtpj20176_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1192\/bjp.169.4.483","volume":"169","author":"K Atkin","year":"1996","unstructured":"Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O\u2019Sullivan D . Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169: 483\u2013488.","journal-title":"Br J Psychiatry"},{"key":"BFtpj20176_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJM199307153290303","volume":"329","author":"JM Alvir","year":"1993","unstructured":"Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA . Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329: 162\u2013167.","journal-title":"N Engl J Med"},{"key":"BFtpj20176_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4088\/JCP.v59n0101","volume":"59","author":"G Honigfeld","year":"1998","unstructured":"Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J . Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59: 3\u20137.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj20176_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1192\/bjp.188.3.255","volume":"188","author":"LR Dunk","year":"2006","unstructured":"Dunk LR, Annan LJ, Andrews CD . Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006; 188: 255\u2013263.","journal-title":"Br J Psychiatry"},{"key":"BFtpj20176_CR7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.schres.2011.10.014","volume":"134","author":"P Manu","year":"2012","unstructured":"Manu P, Sarpal D, Muir O, Kane JM, Correll CU . When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 2012; 134: 180\u2013186.","journal-title":"Schizophr Res"},{"key":"BFtpj20176_CR8","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/0140-6736(92)91625-I","volume":"339","author":"AZ Safferman","year":"1992","unstructured":"Safferman AZ, Lieberman JA, Alvir JM, Howard A . Rechallenge in clozapine-induced agranulocytosis. Lancet 1992; 339: 1296\u20131297.","journal-title":"Lancet"},{"key":"BFtpj20176_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/archderm.1994.01690050066011","volume":"130","author":"PS Friedmann","year":"1994","unstructured":"Friedmann PS, Strickland I, Pirmohamed M, Park BK . Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994; 130: 598\u2013604.","journal-title":"Arch Dermatol"},{"key":"BFtpj20176_CR10","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/0140-6736(92)91877-B","volume":"339","author":"R Jaunkalns","year":"1992","unstructured":"Jaunkalns R, Shear NH, Sokoluk B, Gardner D, Claas F, Uetrecht JP . Antimyeloperoxidase antibodies and adverse reactions to clozapine. Lancet 1992; 339: 1611\u20131612.","journal-title":"Lancet"},{"key":"BFtpj20176_CR11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0026-895X(24)13268-3","volume":"53","author":"I Gardner","year":"1998","unstructured":"Gardner I, Zahid N, MacCrimmon D, Uetrecht JP . A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Mol Pharmacol 1998; 53: 991\u2013998.","journal-title":"Mol Pharmacol"},{"issue":"Suppl 1","key":"BFtpj20176_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2165\/00002018-199200071-00011","volume":"7","author":"JP Uetrecht","year":"1992","unstructured":"Uetrecht JP . Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis. Drug Saf 1992; 7 (Suppl 1): 51\u201356.","journal-title":"Drug Saf"},{"key":"BFtpj20176_CR13","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/S0022-3565(25)12207-6","volume":"275","author":"ZC Liu","year":"1995","unstructured":"Liu ZC, Uetrecht JP . Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J Pharmacol Exp Ther 1995; 275: 1476\u20131483.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtpj20176_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0300-483X(98)00110-3","volume":"131","author":"I Guest","year":"1998","unstructured":"Guest I, Sokoluk B, MacCrimmon J, Uetrecht J . Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology 1998; 131: 53\u201365.","journal-title":"Toxicology"},{"key":"BFtpj20176_CR15","first-page":"247","volume":"31","author":"A Yagcioglu","year":"2011","unstructured":"Yagcioglu A, Cetin Ilhan B, Goktas M, Babaoglu M, Uz E, Yazici M . Agranylocytosis related to clozapine in monozoygotic twins and association with allelic variants of multidrug resistance gene MDR1. Psychopharmacology 2011; 31: 247\u2013248.","journal-title":"Psychopharmacology"},{"key":"BFtpj20176_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/136515001300225231","volume":"5","author":"J Hor\u00e1\u010dek","year":"2001","unstructured":"Hor\u00e1\u010dek J, Libiger C, H\u00f6schl K, Borzova I, Hendrychov\u00e1 J . Clozapine-induced concordant agranulocytosis in monozygotic twins. Int J Psychiatry Clin Pract 2001; 5: 71\u201373.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"BFtpj20176_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ajmg.b.32287","volume":"168","author":"SAJ de With","year":"2015","unstructured":"de With SAJ, Pulit SL, Wang T, Staal WG, Solinge WW van, de Bakker PIW et al. Genome-wide association study of lymphoblast cell viability after clozapine exposure. Am J Med Genet Part B Neuropsychiatr Genet 2015; 168: 116\u2013122.","journal-title":"Am J Med Genet Part B Neuropsychiatr Genet"},{"key":"BFtpj20176_CR18","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","volume":"428","author":"W-H Chung","year":"2004","unstructured":"Chung W-H, Hung S-I, Hong H-S, Hsih M-S, Yang L-C, Ho H-C et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.","journal-title":"Nature"},{"key":"BFtpj20176_CR19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ng.379","volume":"41","author":"AK Daly","year":"2009","unstructured":"Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe\u2019er I, Floratos A et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816\u2013819.","journal-title":"Nat Genet"},{"key":"BFtpj20176_CR20","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","volume":"19","author":"W Tassaneeyakul","year":"2009","unstructured":"Tassaneeyakul W, Jantararoungtong T, Chen P, Lin P-Y, Tiamkao S, Khunarkornsiri U et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19: 704\u2013709.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj20176_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","volume":"359","author":"S Mallal","year":"2002","unstructured":"Mallal S, Nolan D, Witt C, Masel G, Martin A, Moore C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727\u2013732.","journal-title":"Lancet"},{"key":"BFtpj20176_CR22","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1001\/archpsyc.1990.01810220061007","volume":"47","author":"JA Lieberman","year":"1990","unstructured":"Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ . HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990; 47: 945\u2013948.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtpj20176_CR23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1056\/NEJM198008073030602","volume":"303","author":"PH Wooley","year":"1980","unstructured":"Wooley PH, Griffin J, Panayi GS, Batchelor JR, Welsh KI, Gibson TJ . HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med 1980; 303: 300\u2013302.","journal-title":"N Engl J Med"},{"key":"BFtpj20176_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/ejhg.2015.87","volume":"24","author":"C Coleman","year":"2015","unstructured":"Coleman C, Quinn EM, Ryan AW, Conroy J, Trimble V, Mahmud N et al. Common polygenic variation in coeliac disease and confirmation of ZNF335 and NIFA as disease susceptibility loci. Eur J Hum Genet 2015; 24: 291\u2013297.","journal-title":"Eur J Hum Genet"},{"key":"BFtpj20176_CR25","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1136\/annrheumdis-2013-204591","volume":"74","author":"L Bossini-Castillo","year":"2015","unstructured":"Bossini-Castillo L, de Kovel C, Kallberg H, van \u2019t Slot R, Italiaander A, Coenen M et al. A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides. Ann Rheum Dis 2015; 74: e15.","journal-title":"Ann Rheum Dis"},{"key":"BFtpj20176_CR26","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/ng.2667","volume":"45","author":"A Cortes","year":"2013","unstructured":"Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, Leo P et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 2013; 45: 730\u2013738.","journal-title":"Nat Genet"},{"key":"BFtpj20176_CR27","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/ng.381","volume":"41","author":"JC Barrett","year":"2009","unstructured":"Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009; 41: 703\u2013707.","journal-title":"Nat Genet"},{"key":"BFtpj20176_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/iji.12088","volume":"41","author":"WM Howell","year":"2014","unstructured":"Howell WM . HLA and disease: guilt by association. Int J Immunogenet 2014; 41: 1\u201312.","journal-title":"Int J Immunogenet"},{"key":"BFtpj20176_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/mp.2013.74","volume":"19","author":"AK Tiwari","year":"2014","unstructured":"Tiwari AK, Need AC, Lohoff FW, Zai CC, Chowdhury NI, M\u00fcller DJ et al. Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis. Mol Psychiatry 2014; 19: 403\u2013405.","journal-title":"Mol Psychiatry"},{"key":"BFtpj20176_CR30","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1038\/ncomms5757","volume":"5","author":"JI Goldstein","year":"2014","unstructured":"Goldstein JI, Fredrik Jarskog L, Hilliard C, Alfirevic A, Duncan L, Fourches D et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun 2014; 5: 4757.","journal-title":"Nat Commun"},{"key":"BFtpj20176_CR31","doi-asserted-by":"crossref","unstructured":"Legge SE, Hamshere ML, Ripke S, Pardinas AF, Goldstein JI, Rees E et al. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Mol Psychiatry 2016: e-pub ahead of print; doi: 10.1038\/mp.2016.97.","DOI":"10.1038\/mp.2016.97"},{"key":"BFtpj20176_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/gepi.20410","volume":"33","author":"J Little","year":"2009","unstructured":"Little J, Higgins JPT, Ioannidis JPa, Moher D, Gagnon F, Von Elm E et al. STrengthening the REporting of Genetic Association Studies (STREGA)- an extension of the STROBE statement. Genet Epidemiol 2009; 33: 581\u2013598.","journal-title":"Genet Epidemiol"},{"key":"BFtpj20176_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2217\/pgs.15.158","volume":"17","author":"M Leusink","year":"2016","unstructured":"Leusink M, Onland-Moret NC, de Bakker PI, de Boer A, Maitland-van der Zee AH . Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics 2016; 17: 163\u2013180.","journal-title":"Pharmacogenomics"},{"key":"BFtpj20176_CR34","unstructured":"Leusink M Challenges and Opportunities in Pharmacogenomics : Studies in Cardiovascular Disease and Asthma. Thesis, Utrecht University, https:\/\/dspace.library.uu.nl\/handle\/1874\/308496, 2015."},{"issue":"Suppl 1","key":"BFtpj20176_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2165\/00002018-199200071-00006","volume":"7","author":"K Abt","year":"1992","unstructured":"Abt K, G\u00fclich A, Krupp P, Reinberg W . HLA-associations in leponex\/clozaril (clozapine)-induced granulocytopenia and agranulocytosis. statistical viewpoints. Drug Saf 1992; 7 (Suppl 1): 10\u201316.","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"BFtpj20176_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2165\/00002018-199200071-00005","volume":"7","author":"JJ Yunis","year":"1992","unstructured":"Yunis JJ, Lieberman J, Yunis EJ . Major histocompatibility complex associations with clozapine-induced agranulocytosis. The USA experience. Drug Saf 1992; 7 (Suppl 1): 7\u20139.","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"BFtpj20176_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2165\/00002018-199200071-00004","volume":"7","author":"FH Claas","year":"1992","unstructured":"Claas FH, Abbott PA, Witvliet MD, D\u2019Amaro J, Barnes PM, Krupp P . No direct clinical relevance of the human leucocyte antigen (HLA) system in clozapine-induced agranulocytosis. Drug Saf 1992; 7 (Suppl 1): 3\u20136.","journal-title":"Drug Saf"},{"key":"BFtpj20176_CR38","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V86.3.1177.1177","volume":"86","author":"JJ Yunis","year":"1995","unstructured":"Yunis JJ, Corzo D, Salazar M, Lieberman JA, Howard A, Yunis EJ . HLA associations in clozapine-induced agranulocytosis. Blood 1995; 86: 1177\u20131183.","journal-title":"Blood"},{"key":"BFtpj20176_CR39","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1182\/blood.V89.11.4167","volume":"89","author":"D Turbay","year":"1997","unstructured":"Turbay D, Lieberman J, Alper CA, Delgado JC, Corzo D, Yunis JJ et al. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood 1997; 89: 4167\u20134174.","journal-title":"Blood"},{"key":"BFtpj20176_CR40","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood.V86.10.3835.bloodjournal86103835","volume":"86","author":"D Corzo","year":"1995","unstructured":"Corzo D, Yunis JJ, Salazar M, Lieberman JA, Howard A, Awdeh Z et al. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 1995; 86: 3835\u20133840.","journal-title":"Blood"},{"key":"BFtpj20176_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1017\/S1461145798001023","volume":"1","author":"A Amar","year":"1998","unstructured":"Amar A, Segman RH, Shtrussberg S, Sherman L, Safirman C, Lerer B et al. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201. Int J Neuropsychopharmacol 1998; 1: 41\u201344.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFtpj20176_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1046\/j.1365-2370.1998.00091.x","volume":"25","author":"A Valevski","year":"1998","unstructured":"Valevski A, Klein T, Gazit E, Meged S, Stein D, Elizur A et al. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet 1998; 25: 11\u201313.","journal-title":"Eur J Immunogenet"},{"key":"BFtpj20176_CR43","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1055\/s-2000-8359","volume":"33","author":"M Dettling","year":"2000","unstructured":"Dettling M, Sachse C, Muller-Oerlinghausen B, Roots I, Brockmoller J, Rolfs A et al. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry 2000; 33: 218\u2013220.","journal-title":"Pharmacopsychiatry"},{"key":"BFtpj20176_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/00008571-200103000-00004","volume":"11","author":"M Dettling","year":"2001","unstructured":"Dettling M, Schaub RT, Mueller-Oerlinghausen B, Roots I, Cascorbi I . Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics 2001; 11: 135\u2013141.","journal-title":"Pharmacogenetics"},{"key":"BFtpj20176_CR45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/archpsyc.58.1.93","volume":"58","author":"M Dettling","year":"2001","unstructured":"Dettling M, Cascorbi I, Roots I, Mueller-Oerlinghausen B . Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-Jewish Caucasian sample. Arch Gen Psychiatry 2001; 58: 93\u201394.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtpj20176_CR46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/00004714-200102000-00002","volume":"21","author":"L Lahdelma","year":"2001","unstructured":"Lahdelma L, Ahokas A, Andersson LC, Suvisaari J, Hovatta I, Huttunen MO et al. Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia. J Clin Psychopharmacol 2001; 21: 4\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"BFtpj20176_CR47","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1046\/j.1399-0039.2003.00133.x","volume":"62","author":"O Ostrousky","year":"2003","unstructured":"Ostrousky O, Meged S, Loewenthal R, Valevski A, Weizman A, Carp H et al. NQO2 gene is associated with clozapine-induced agranulocytosis. Tissue Antigens 2003; 62: 483\u2013491.","journal-title":"Tissue Antigens"},{"key":"BFtpj20176_CR48","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/01.jcp.0000177551.13714.33","volume":"25","author":"I Mosyagin","year":"2005","unstructured":"Mosyagin I, Cascorbi I, Schaub R, Kr\u00fcger T, Dettling M . Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms? J Clin Psychopharmacol 2005; 25: 435\u2013440.","journal-title":"J Clin Psychopharmacol"},{"key":"BFtpj20176_CR49","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/01.jcp.0000144891.52858.a6","volume":"24","author":"I Mosyagin","year":"2004","unstructured":"Mosyagin I, Dettling M, Roots I, Mueller-Oerlinghausen B, Cascorbi I . Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol 2004; 24: 613\u2013617.","journal-title":"J Clin Psychopharmacol"},{"key":"BFtpj20176_CR50","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/sj.tpj.6500423","volume":"7","author":"M Dettling","year":"2007","unstructured":"Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R . Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J 2007; 7: 325\u2013332.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj20176_CR51","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4088\/JCP.09m05527yel","volume":"72","author":"MC Athanasiou","year":"2011","unstructured":"Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 2011; 72: 458\u2013463.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj20176_CR52","doi-asserted-by":"crossref","unstructured":"van der Weide K, Loovers H, Pondman K, Bogers J, van der Straaten T, Langemeijer E et al. Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population. Pharmacogenomics J 2016; e-pub ahead of print; doi: 10.1038\/tpj.2016.32.","DOI":"10.1038\/tpj.2016.32"},{"key":"BFtpj20176_CR53","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/JCP.0000000000000495","volume":"36","author":"AE An\u0131l Ya\u011fcio\u011flu","year":"2016","unstructured":"An\u0131l Ya\u011fcio\u011flu AE, Yoca G, Ayhan Y, Karaca R\u00d6, \u00c7evik L, M\u00fcderriso\u011flu A et al. Relation of the allelic variants of multidrug resistance gene to agranulocytosis associated with clozapine. J Clin Psychopharmacol 2016; 36: 257\u2013261.","journal-title":"J Clin Psychopharmacol"},{"key":"BFtpj20176_CR54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00125817-200203000-00002","volume":"4","author":"JN Hirschhorn","year":"2002","unstructured":"Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K . A comprehensive review of genetic association studies. Genet Med 2002; 4: 45\u201361.","journal-title":"Genet Med"},{"key":"BFtpj20176_CR55","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/mp.2015.16","volume":"20","author":"MS Farrell","year":"2015","unstructured":"Farrell MS, Werge T, Sklar P, Owen MJ, Ophoff Ra, O\u2019Donovan MC et al. Evaluating historical candidate genes for schizophrenia. Mol Psychiatry 2015; 20: 555\u2013562.","journal-title":"Mol Psychiatry"},{"key":"BFtpj20176_CR56","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/tpj.2015.5","volume":"15","author":"M Verbelen","year":"2015","unstructured":"Verbelen M, Collier DA, Cohen D, MacCabe JH, Lewis CM . Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis. Pharmacogenomics J 2015; 15: 461\u2013466.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj20176_CR57","unstructured":"Abecasis G . Power Calculations: Quantitative Traits. 2014. Available at: http:\/\/genome.sph.umich.edu\/wiki\/Power_Calculations:_Quantitative_Traits."},{"key":"BFtpj20176_CR58","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"J van Os","year":"2009","unstructured":"van Os J, Kapur S . Schizophrenia. Lancet 2009; 374: 635\u2013645.","journal-title":"Lancet"},{"key":"BFtpj20176_CR59","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","volume":"50","author":"RR Conley","year":"2001","unstructured":"Conley RR, Kelly DL . Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50: 898\u2013911.","journal-title":"Biol Psychiatry"},{"key":"BFtpj20176_CR60","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1176\/appi.ajp.2015.15030332","volume":"173","author":"TS Stroup","year":"2016","unstructured":"Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M . Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry 2016; 173: 166\u2013173.","journal-title":"Am J Psychiatry"},{"key":"BFtpj20176_CR61","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/070674370304800709","volume":"48","author":"D Zullino","year":"2003","unstructured":"Zullino D, Conus P, Borgeat F, Bonsack C . Readiness to participate in psychiatric research. Can J Psychiatry 2003; 48: 480\u2013484.","journal-title":"Can J Psychiatry"},{"key":"BFtpj20176_CR62","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1471-244X-14-28","volume":"14","author":"R J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen R, Munk-J\u00f8rgensen P, Lysaker PH, Buck KD, Hansson L, Zoffmann V . Overcoming recruitment barriers revealed high readiness to participate and low dropout rate among people with schizophrenia in a randomized controlled trial testing the effect of a guided self-determination intervention. BMC Psychiatry 2014; 14: 28.","journal-title":"BMC Psychiatry"},{"key":"BFtpj20176_CR63","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"S Ripke","year":"2014","unstructured":"Ripke S, Neale BM, Corvin A, Walters JTR, Farh K-H, Holmans PA et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511: 421\u2013427.","journal-title":"Nature"},{"key":"BFtpj20176_CR64","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1176\/appi.ajp.2008.08091354","volume":"166","author":"S Cichon","year":"2009","unstructured":"Cichon S, Craddock N, Daly M, Faraone SV, Gejman PV, Kelsoe J et al. Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am J Psychiatry 2009; 166: 540\u2013556.","journal-title":"Am J Psychiatry"},{"key":"BFtpj20176_CR65","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/ng.3097","volume":"46","author":"AR Wood","year":"2014","unstructured":"Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S et al. Defining the role of common variation in the genomic and biological architecture of adult human height. Nat Genet 2014; 46: 1173\u20131186.","journal-title":"Nat Genet"},{"key":"BFtpj20176_CR66","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/mp.2013.138","volume":"19","author":"DM Ruderfer","year":"2014","unstructured":"Ruderfer DM, Fanous AH, Ripke S, McQuillin A, Amdur RL, Gejman PV et al. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol Psychiatry 2014; 19: 1017\u20131024.","journal-title":"Mol Psychiatry"},{"key":"BFtpj20176_CR67","doi-asserted-by":"publisher","first-page":"e12600","DOI":"10.1371\/journal.pone.0012600","volume":"5","author":"SL Pulit","year":"2010","unstructured":"Pulit SL, Voight BF, de Bakker PIW . Multiethnic genetic association studies improve power for locus discovery. PLoS ONE 2010; 5: e12600.","journal-title":"PLoS ONE"},{"key":"BFtpj20176_CR68","doi-asserted-by":"publisher","first-page":"99","DOI":"10.9758\/cpn.2012.10.2.99","volume":"10","author":"T-M Si","year":"2012","unstructured":"Si T-M, Zhang Y-S, Shu L, Li K-Q, Liu X-H, Mei Q-Y et al. Use of clozapine for the treatment of schizophrenia: findings of the 2006 research on the China psychotropic prescription studies. Clin Psychopharmacol Neurosci 2012; 10: 99\u2013104.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"BFtpj20176_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-2007-993224","volume":"41","author":"Y-L Tang","year":"2008","unstructured":"Tang Y-L, Mao P-X, Jiang F, Chen Q, Wang C-Y, Cai Z-J et al. Clozapine in China. Pharmacopsychiatry 2008; 41: 1\u20139.","journal-title":"Pharmacopsychiatry"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj20176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj20176","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/tpj.2017.6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/tpj20176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T22:48:50Z","timestamp":1750200530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj20176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,18]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["BFtpj20176"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2017.6","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,18]]},"assertion":[{"value":"8 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}